Clinical Trial Detail

NCT ID NCT02179671
Title Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Recruitment Completed
Gender
Phase Phase II
Variant Requirements no
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Docetaxel + Selumetinib

Gefitinib

Durvalumab

Osimertinib

Tremelimumab

Age Groups:

No variant requirements are available.